Markus Reschke

Novartis · company speakers →

took turns talking about the properties of FXX489, a radioligand therapy that targets fibroblast activation protein (FAP).

Is this you? Claim this profile →

No public contact links on file.

Speaking history

AACR Drug Discovery and Development (AACR D3)

21 July 2026 Boston, United States “FXX489: Stromal-targeting Radioligand in Breast, Colorectal, Lung, and Pancreatic Cancers”

Sourcing speakers for your event?

Browse the speaker directory →